 SAN DIEGO--BUSINESS WIRE--Ligand Pharmaceuticals Incorporated NASDAQ: LGND announced today a collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline GSK to leverage Icagens unique expertise in small molecule therapeutics targeting transmembrane proteins. This collaboration will utilize the Icagen discovery technology to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases. We are very pleas 